You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
| Title |
Nivolumab plus ipilimumab in the treatment of advanced melanoma
|
|---|---|
| Published in |
Journal of Hematology & Oncology, October 2015
|
| DOI | 10.1186/s13045-015-0219-0 |
| Pubmed ID | |
| Authors |
Katy K. Tsai, Adil I. Daud |
| Abstract |
Advanced melanoma has historically been a difficult disease to treat due to few effective systemic treatment options. However, over the past few years, scientific advancements in immune checkpoint inhibition have resulted in several novel approaches that have changed front-line management of advanced melanoma. Despite these exciting developments, there remains room for improvement in treatment outcomes. Combination immunotherapy, in particular combined cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed death 1 (PD-1) blockade, represents an important first step in this direction. |
Mendeley readers
The data shown below were compiled from readership statistics for 67 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 67 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 12 | 18% |
| Student > Ph. D. Student | 8 | 12% |
| Student > Master | 8 | 12% |
| Student > Bachelor | 7 | 10% |
| Student > Doctoral Student | 6 | 9% |
| Other | 12 | 18% |
| Unknown | 14 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 21 | 31% |
| Agricultural and Biological Sciences | 12 | 18% |
| Biochemistry, Genetics and Molecular Biology | 8 | 12% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 4% |
| Mathematics | 2 | 3% |
| Other | 7 | 10% |
| Unknown | 14 | 21% |